Pencoed, UK, 8 June 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to provide an update on progress with the ongoing US Phase I/II dose escalation study of its human retinal progenitor cell (hRPC) therapy candidate in patients with advanced retinitis pigmentosa (RP).

Read more…

A great-grandfather becomes one of the first in the UK to be treated for a stroke, using stem cells.

Watch video: http://www.bbc.co.uk/news/health-36450628.

Pencoed, UK, 15 March 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that the first patient has been treated with the Company’s cell therapy candidate for the blindness-causing disease retinitis pigmentosa (RP) in a first-in-human US clinical trial.  The procedure, involving a single injection of hRPC cells under the retina, was conducted at Massachusetts Eye and Ear in Boston, a teaching affiliate of Harvard Medical School (HMS) and a world-renowned clinical and research centre for the treatment of eye disease, including retinal degeneration. The patient was discharged from hospital on the same day.

Read More…

 

 

Guildford, UK, 23 February 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that, from 29 February 2016, its headquarters, research laboratories and manufacturing facilities will be located at a new purpose-built building on the Pencoed Business Park, just off the M4 motorway at Pencoed, South Wales.

Read more…

Guildford, UK, 1 February 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has received a Notice of Allowance from the US Patent and Trademark Office for a key patent application covering its cell cryopreservation technology.

Read more…

Guildford, UK, 11 January 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has been awarded a £2.1 million grant from Innovate UK to further advance its emerging exosome nanomedicine platform.

Read more…

Guildford, UK, 17 December 2015: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has held the inaugural meeting of its newly-established Scientific Advisory Board (“SAB”), which comprises nine leading academics and industry executives with a world-class breadth of expertise across the Company’s areas of operation. The meeting was chaired by Dr Mike Owen, who was recently appointed as a Non-executive Director of the Company.

Read more…

Guildford, UK, 7 December 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce its interim results for the six months ended 30 September 2015.

Read more…

Guildford, UK, 4 December 2015: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce the appointment of Dr Mike Owen as a Non-executive Director of the Company with immediate effect.   He will also chair the Company’s Scientific Advisory Board.

Read more…